KPV vs Selank
Both compounds are short synthetic peptides with immunomodulatory research profiles, but they operate through different pathways and have been studied in different model systems. KPV is a melanocortin-derived tripeptide studied for NF-κB inhibition in intestinal inflammation. Selank is a tuftsin analogue studied for GABAergic modulation and cytokine-profile effects in the CNS. This page summarises the published distinctions.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Structural class | Tripeptide (Lys-Pro-Val); α-MSH C-terminal fragment | Heptapeptide; tuftsin analogue with Pro-Gly-Pro extension |
| Approximate molecular weight | 342.4 g/mol | 863.0 g/mol |
| Best-studied mechanism | NF-κB pathway inhibition; PepT1-mediated intestinal uptake | GABAergic-neurotransmission gene modulation; BDNF regulation; cytokine-profile effects |
| Primary research domain | Intestinal inflammation, colonic mucosa, skin inflammation | Central nervous system, anxiolytic endpoints, immunomodulation |
| Common research routes | Intraperitoneal, oral, topical in rodent models | Intranasal, intraperitoneal in rodent studies |
| Ronin catalog vial size | 10 mg lyophilised | 10 mg lyophilised |
How they differ in mechanism
KPV is derived from the C-terminal tripeptide of alpha-melanocyte-stimulating hormone and has been studied for NF-κB pathway inhibition. The Dalmasso et al. work demonstrated PepT1-mediated uptake in intestinal epithelial cells and downstream inhibition of NF-κB-driven inflammatory signalling. The functional endpoints centre on colitis severity, intestinal-barrier integrity, and inflammation-associated cancer models.
Selank is a tuftsin analogue with a Pro-Gly-Pro C-terminal extension that confers protease resistance. The published mechanistic literature describes modulation of GABAergic-neurotransmission gene expression, BDNF regulation in hippocampal and prefrontal tissue, and cytokine-profile changes under stress conditions. The immunomodulatory component is mediated through cytokine modulation rather than through NF-κB pathway inhibition.
Both compounds have immunomodulatory research profiles, but the downstream pathways differ: KPV acts on NF-κB in intestinal epithelium, while Selank modulates cytokine profiles and GABAergic gene expression in the CNS. The immunomodulatory overlap is at the categorical level rather than at a shared mechanistic target.
How research has examined each
The KPV literature centres on colitis models (Dalmasso, Kannengiesser, Viennois) and delivery-system research (Xiao nanoparticles, Sun hydrogels). The compound’s position as a fragment of alpha-MSH provides melanocortin-pathway context, though the compound-specific work focuses on NF-κB-level inflammation modulation.
The Selank literature centres on GABAergic gene expression (Volkova, Filatova), BDNF and memory endpoints (Dolotov, Kolik), stress-related cytokine modulation (Leonidovna), and morphine-withdrawal attenuation (Konstantinopolsky). The compound’s tuftsin backbone provides immunomodulatory context from the innate-immunity peptide field.
The two literatures share the broad immunomodulatory peptide category but do not cite each other in primary research. The model systems, journals, and lead authors are distinct.
Stacking considerations in research contexts
Combined administration is not described in the published literature. The downstream pathways differ (NF-κB intestinal inflammation versus GABAergic CNS modulation). No combined-protocol data exist. Both compounds are sold as separate 10 mg lyophilised vials in the Ronin catalog.
Sourcing both at Ronin
Both compounds in the Ronin catalog ship as 10 mg lyophilised peptide in glass vials, capped and crimped, with certificate-of-analysis documentation on the lab-results page. The KPV vial page and the Selank vial page carry per-compound spec sheets. Both are sold strictly as research-grade reagents.
Frequently asked research questions
Are KPV and Selank related?
No. KPV is an alpha-MSH-derived tripeptide. Selank is a tuftsin-derived heptapeptide. Different precursors, sequences, and mechanisms.
Both have immunomodulatory properties — do they target the same pathway?
No. KPV inhibits NF-kappa-B in intestinal epithelium. Selank modulates cytokine profiles and GABAergic gene expression in the CNS. The immunomodulatory overlap is categorical, not mechanistic.
Are they stacked?
Not in published research.
Do they share storage practice?
Yes. Both are lyophilised peptides, reconstituted in bacteriostatic water, stored at 2-8 degrees Celsius.
Are either approved for human use?
Neither is approved by the FDA or Health Canada. Both are research-grade reagents.
References
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008. [PMID 18061177]
- Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 2008. [PMID 18092346]
- Volkova A et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology, 2016. [PMID 26924987]
- Kolik LG et al. Selank protects against ethanol-induced memory impairment by regulating BDNF content. Bulletin of Experimental Biology and Medicine, 2019. [PMID 31625062]
- Konstantinopolsky MA et al. Selank attenuates aversive signs of morphine withdrawal in rats. Bulletin of Experimental Biology and Medicine, 2022. [PMID 36322304]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.